Endometrial expression of epithelial neutrophil-activating peptide-78 during the menstrual cycle or in progestin-only contraceptive users with breakthrough bleeding and the influence of doxycycline therapy.
BACKGROUND
Endometrial breakthrough bleeding is characterized by an inflammatory reaction and increased production of proinflammatory mediators, one of which may be epithelial neutrophil-activating peptide-78 (ENA-78), a chemokine with neutrophil-activating properties.


RESULTS
We therefore investigated the endometrial expression of ENA-78 in Norplant users as progestin-only contraceptive with various bleeding patterns (n=35) as compared with non-users with a normal menstrual cycle (n=55). The endometrial stromal cells (ESCs) were the major site of ENA-78 expression with the highest levels found during the secretory phase. The expression of ENA-78 was increased in Norplant users with irregular bleeding as compared with those with regular cycles and amenorrhoea. The levels of ENA-78 detected in uterine washes and sera after the use of Norplant for 3-6 months (n=25) increased compared with baseline (P < 0.05). These levels did not significantly change in Norplant users who received doxycycline (Dox) therapy (25 mg/twice daily for 6 months) when measured midway through or at the conclusion of study when compared with the baseline (n=25). Treatments with medroxyprogesterone acetate (MPA) and tumour necrosis factor-alpha (TNF-alpha) (25 ng/ml), but not 17beta-estradiol (E2) or E2 + MPA (10(-8) M), representing endometrium exposed to contraceptive and inflammatory conditions, respectively, increased the levels of ENA-78 production by ESCs, and this was reduced by co-treatments with Dox (25 microg/ml) (P < 0.05).


CONCLUSIONS
The endometrial production of ENA-78 is altered in progestin-only contraceptive users experiencing breakthrough bleeding and is regulated by MPA and TNF-alpha in ESCs. Although Dox therapy did not alter uterine ENA-78 secretion, its suppression in ESCs suggests that Dox, acting site-specifically and through an anti-inflammatory mechanism, may influence the outcome of breakthrough bleeding in contraceptive users.
Chegini
N
N
Department of Obstetrics/Gynecology, University of Florida, Gainesville, FL 32610-0294, USA. cheginin@obgyn.ufl.edu
Luo
X
X
Pan
Q
Q
Rhoton-Vlasak
A
A
Archer
D F
DF
D000293:Adolescent; D000328:Adult; D054365:Chemokine CXCL5; D019743:Chemokines, CXC / Q000096:biosynthesis*; D003271:Contraceptive Agents, Female / Q000627:therapeutic use*; D004318:Doxycycline / Q000627:therapeutic use*; D004717:Endometrium / Q000166:cytology / Q000378:metabolism*; D005260:Female; D005498:Follicular Phase / Q000502:physiology; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D016912:Levonorgestrel / Q000627:therapeutic use*; D008183:Luteal Phase / Q000502:physiology; D017154:Stromal Cells / Q000378:metabolism; D014592:Uterine Hemorrhage / Q000503:physiopathology*
C486263:CXCL5 protein, human; D054365:Chemokine CXCL5; D019743:Chemokines, CXC; D003271:Contraceptive Agents, Female; D016912:Levonorgestrel; D004318:Doxycycline